Abstract is: Drugs used in diabetes treat diabetes mellitus by altering the glucose level in the blood. With the exceptions of insulin, most GLP receptor agonists (liraglutide, exenatide, and others), and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors. Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in type 1, which must be injected. Diabetes mellitus type 2 is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase loss of glucose through urination. Several groups of drugs, mostly given by mouth, are effective in type 2, often in combination. The therapeutic combination in type 2 may include insulin, not necessarily because oral agents have failed completely, but in search of a desired combination of effects. The great advantage of injected insulin in type 2 is that a well-educated patient can adjust the dose, or even take additional doses, when blood glucose levels measured by the patient, usually with a simple meter, as needed by the measured amount of sugar in the blood.
| ChEBI Ontology term | Q41014950 |
| physiological effect of drugs | Q50379782 |
| medication | Q12140 |
| P267 | ATC code | A10 |
| P683 | ChEBI ID | 35526 |
| P4746 | Elhuyar ZTH ID | 134342 |
| P646 | Freebase ID | /m/01lml6 |
| P12385 | Gran Enciclopèdia Catalana ID | hipoglucemiant |
| P1296 | Gran Enciclopèdia Catalana ID (former scheme) | 0114588 |
| P7830 | LiverTox ID | Antidiabetic |
| P486 | MeSH descriptor ID | D007004 |
| P672 | MeSH tree code | D27.505.696.422 |
| P6366 | Microsoft Academic ID | 2777334876 |
| 2909356532 | ||
| P691 | NL CR AUT ID | ph134712 |
| P1245 | OmegaWiki Defined Meaning | 1302820 |
| P10283 | OpenAlex ID | C2910525902 |
| P3417 | Quora topic ID | Anti-diabetic-Medication |
| P5082 | Store medisinske leksikon ID | antidiabetika |
| P11143 | WikiProjectMed ID | Diabetes medication |
| P366 | has use | diabetes management | Q1100933 |
| P910 | topic's main category | Category:Anti-diabetic drugs | Q8255706 |
| Q116585334 | PPAR-gamma agonists |
| Q4734932 | alpha-glucosidase inhibitor |
| Q50430476 | amylin receptor agonists |
| Q115650104 | biguanide |
| Q419770 | dipeptidyl peptidase-4 inhibitors |
| Q20089925 | gliflozins |
| Q5572286 | glucagon-like peptide-1 agonist |
| Q50430474 | glycoside hydrolase inhibitors |
| Q116559614 | insulin secretagogues |
| Q76789487 | lente insulin |
| Q114049592 | thiazolidindiones |
| Q7880550 | ultralente insulin |
| Q4449253 | Таблетированные сахароснижающие средства |
| Q81977189 | (1R,2S)-butaxamine |
| Q27077245 | (R)-etomoxir |
| Q424771 | (RS)-rosiglitazone |
| Q139883 | (±)-L-alliin |
| Q1393556 | 2,4-thiazolidinedione |
| Q27268159 | 2-bromopalmitic acid |
| Q3492616 | Insulin Lispro |
| Q27098274 | Lecanoric acid |
| Q1929845 | NPH insulin |
| Q104948060 | Reticulatin A |
| Q105204346 | Trivaric acid |
| Q4673274 | acetohexamide |
| Q2817102 | aicar |
| Q409641 | allicin |
| Q4734170 | alogliptin |
| Q31749378 | atranorin |
| Q27075007 | bempedoic acid |
| Q142880 | biguanide |
| Q715104 | buformin |
| Q5030940 | canagliflozin |
| Q5038107 | carbutamide |
| Q1075324 | chlorpropamide |
| Q5119890 | ciglitazone |
| Q27275433 | cl-316243 |
| Q27147567 | diphenyleneiodonium |
| Q21011228 | dulaglutide |
| Q5373824 | empagliflozin |
| Q5378714 | englitazone |
| Q27269857 | ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate |
| Q417762 | exenatide |
| Q3772225 | glibornuride |
| Q290001 | gliclazide |
| Q425027 | glimepiride |
| Q3108899 | glipizide |
| Q5569924 | gliquidone |
| Q420626 | glyburide |
| Q10910504 | gusperimus |
| Q2244355 | gyrophoric acid |
| Q50265665 | insulin |
| Q2754775 | insulin aspart |
| Q410965 | insulin detemir |
| Q417317 | insulin glargine |
| Q6042242 | insulin glulisine |
| Q909745 | linagliptin |
| Q2526479 | liraglutide |
| Q6659956 | lixisenatide |
| Q27271068 | meglitinide |
| Q19484 | metformin |
| Q27284987 | methyl palmoxirate |
| Q27258755 | midaglizole |
| Q772735 | miglitol |
| Q266321 | mitiglinide |
| Q2254797 | nateglinide |
| Q27088241 | palmoxiric acid |
| Q753100 | phenformin |
| Q25100298 | phenylbiguanide |
| Q417765 | pioglitazone |
| Q27164918 | ponalrestat |
| Q2062094 | pramlintide |
| Q2195995 | repaglinide |
| Q103817922 | sekikaic acid |
| Q27290248 | sitagliptin phosphate hydrate |
| Q7636496 | sulodexide |
| Q108324770 | tirzepatide |
| Q7814101 | tolazamide |
| Q414275 | tolbutamide |
| Q7844989 | troglitazone |
| Q413634 | vanadyl sulfate |
| Q7939403 | voglibose |
| Q27136451 | zeorin |
| Q27089300 | zopolrestat |
| Q121986553 | Antidiabetika: historie, současnost a perspektivy |
| Q121988771 | Antidiabetika: historie, současnost a perspektivy |
| Q121988438 | Kombinovaná antidiabetická terapie s inzulinem při diabetes mellitus 2. typu |
| Q121975974 | Ledviny a léčba diabetu: současnost a perspektivy terapie glifloziny |
| Q121961001 | Pět let zkušeností s liraglutidem |
| Q39613410 | "First" and "second" generation sulfonylureas: distinction or difference? (author's transl) |
| Q76634920 | "THE TOLBUTAMIDE TOLERANCE TEST, THE EFFECTS OF CHLOROTHIAZIDE ON GLUCOSE METABOLISM, AND THE PRESENT STATUS OF ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF DIABETES" |
| Q72710195 | 1-Acyl-1-alkoxy-3-(p-tolylsulfonyl)ureas1 |
| Q78417174 | 2 CASES OF HEMIPLEGIA INDICATIVE OF SEVERE HYPOGLYCEMIA INDUCED BY HYPOGLYCEMIC SULFONAMIDES |
| Q94304804 | 40 YEARS OF INSULIN AND INTERMEDIATE METABOLISM |
| Q76620733 | A CLINICAL TRIAL OF AN ORAL HYPOGLYCEMIC AGENT IN CHRONIC SCHIZOPHRENIC PATIENTS |
| Q78920978 | A Hypoglycemic Factor in Leukemic Tumors |
| Q76860541 | A NEW ORAL HYPOGLYCEMIC AGENT: ACETOHEXAMIDE. PERSONAL RESULTS |
| Q71743670 | A Quantum Chemical Study with Special Reference to the Sulfamyl Group of Sulfonylureas |
| Q35424562 | A REVIEW OF THE HISTORY OF THE TREATMENT OF DIABETES MELLITUS AND THE SEARCH FOR ORAL HYPOGLYCAEMIC AGENTS |
| Q38694894 | A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. |
| Q76786377 | A STUDY IN RETROSPECT OF HOSPITALISED PATIENTS OF DIABETES MELLITUS IN SOUTH INDIA |
| Q40039662 | A Survey of Diabetes Mellitus |
| Q35656190 | A Systematic Review of Interventions Addressing Adherence to Anti-Diabetic Medications in Patients with Type 2 Diabetes--Components of Interventions |
| Q37556648 | A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. |
| Q47158512 | A core outcomes set for clinical trials of interventions for young adults with type 1 diabetes: an international, multi-perspective Delphi consensus study. |
| Q78909990 | A new oral hypoglycemic drug: DBI. Preliminary report of 3 cases |
| Q41354131 | A new perspective on metformin therapy in type 1 diabetes |
| Q26995462 | A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients |
| Q78861236 | A review of antidiabetic sulfonylureas |
| Q38802810 | A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. |
| Q38910367 | A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes |
| Q37853658 | A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations |
| Q36596836 | A review of nateglinide in the management of patients with type 2 diabetes. |
| Q35536225 | A review of oral hypoglycemic agents |
| Q34436383 | A review of the pharmacological properties of insulin degludec and their clinical relevance |
| Q36596873 | A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications |
| Q35116984 | A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes--impact on adherence |
| Q76885176 | ACETOHEXAMIDE ('DIMELOR') IN DIABETES |
| Q76792004 | ACETOHEXAMIDE, A NEW ORAL HYPOGLYCEMIC AGENT. A PRELIMINARY REPORT OF A CLINICAL TRIAL |
| Q76845220 | ACETOHEXAMIDE--A NEW ORAL AGENT FOR CONTROL OF DIABETES MELLITUS. A PRELIMINARY REPORT |
| Q76757704 | ACETOHEXAMIDE: CLINICAL EVALUATION OF A NEW ORAL ANTIDIABETIC AGENT |
| Q76897738 | ACTION OF A HYPOGLYCEMIC SULFONAMIDE (TOLBUTAMIDE) ON THE GLYCOGEN CONTENT OF HEPATOCYTES IN CULTURE; COMPARISON WITH THE ACTION OF GLUCAGON |
| Q76642508 | ACTION OF ACETOHEXAMIDE ON DIABETIC HYPERGLYCEMIA |
| Q76850776 | ACTION OF HYPOGLYCEMIC DRUGS ON THE LIVER |
| Q76961706 | ACTION OF HYPOGLYCEMIC SULFONAMIDES ON THE PRODUCTION OF CO2 BY ADIPOSE TISSUE OF THE RAT EPIDIDYMIS "IN VITRO" |
| Q76540770 | ACTIVITIES OF GLUCOSE-6-PHOSPHATASE AND HEXOKINASE UNDER THE EFFECT OF N1,N-BUTYLBIGUANIDE |
| Q64251759 | AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases |
| Q27002908 | AMPK: a target for drugs and natural products with effects on both diabetes and cancer |
| Q78565303 | ANAEROBIC GLYCOLYSIS IN EHRLICH ASCITES TUMOR CELLS. 2. ALTERATION BY ANTIDIABETICS |
| Q76701762 | ANALYSIS OF 81 CASES OF "PREGNANCY DIABETOID STATE" TREATED WITH ORAL ANTIDIABETICS |
| Q76785987 | ANTIDIABETIC ACTION OF HYPOGLYCEMIC SULFONAMIDE (CHLORPROPAMIDE) ON EXPERIMENTAL LATENT DIABETES IN DOGS |
| Q78369428 | ANTIDIABETIC CAMPAIGN. THE FUTURE OF THE DIABETIC |
| Q78291576 | APROPOS OF A NEW ORAL ANTIDIABETIC, S.H. 717 |
| Q76866308 | ARE TABLETS FOR DIABETES JUST DRUGS OF CONVENIENCE? |
| Q76719451 | ARTERITIS OF THE EXTREMITIES IN DIABETICS. I. CLINICAL ASPECTS AND THERAPY. STUDY OF 100 CASES |
| Q76797582 | ASSOCIATION OF 2 ANTIDIABETIC DRUGS FOR ORAL USE WITH AMP, THIAMINE AND VITAMIN B 12 IN THE TREATMENT OF DIABETIC POLYNEURITIS |
| Q76833714 | ASSOCIATION OF PULMONARY TUBERCULOSIS AND DIABETES MELLITUS |
| Q53042073 | AZEPINAMIDE IN THE THERAPY OF DIABETES MELLITUS |
| Q34563587 | Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options |
| Q79049298 | Action of the hypoglycemic sulfonamide D 860 on sections of rat organs |
| Q55516148 | Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. |
| Q38123792 | Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes |
| Q33476850 | Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis |
| Q36546914 | Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy |
| Q58099964 | Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review |
| Q38806457 | Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development |
| Q78980350 | Adenoma of the islets of Langerhans and hypoglycemic accidents. A propos of surgically-treated cases |
| Q28068120 | Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy |
| Q26786265 | Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis |
| Q42654509 | Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. |
| Q52373049 | Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease. |
| Q78913488 | Amelioration of human hypoglycemic symptoms by intravenous fructose |
| Q67428438 | Amides and hydrazines of oxalic acid. The synthesis and hypoglycemic activity of the alkylamides of oxalic arensulfohydrazides |
| Q35585217 | An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. |
| Q28385065 | An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides |
| Q35278160 | An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials |
| Q33902616 | An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog |
| Q78787844 | Analeptic action of peripheral electrical stimulation in hypoglycemic coma |
| Q92129946 | Anti-Diabetic Effects and Mechanisms of Dietary Polysaccharides |
| Q26781424 | Anti-Diabetic Potential of Noni: The Yin and the Yang |
| Q64991012 | Anti-Obesity and Anti-Diabetic Effects of Ishige okamurae. |
| Q39898035 | Anti-diabetic drugs in the private and public sector in Dar es Salaam, Tanzania |
| Q44273296 | Antidiabetic Action of Vanadyl in Rats Independent of in Vivo Insulin-Receptor Kinase Activity |
| Q70264238 | Antidiabetic Behavior of Biguanides |
| Q33800802 | Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives |
| Q43373021 | Antidiabetic Effect of Brain-Derived Neurotrophic Factor and Its Association with Inflammation in Type 2 Diabetes Mellitus |
| Q37512665 | Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility. |
| Q39322313 | Antidiabetic Effects of Tea. |
| Q26738814 | Antidiabetic Medicinal Plants Used by the Basotho Tribe of Eastern Free State: A Review |
| Q90419939 | Antidiabetic Potential of Medicinal Plants and Their Active Components |
| Q47173290 | Antidiabetic Potential of Monoterpenes: A Case of Small Molecules Punching above Their Weight |
| Q64100894 | Antidiabetic Properties of Naringenin: A Citrus Fruit Polyphenol |
| Q37244395 | Antidiabetic potential of the heme oxygenase-1 inducer curcumin analogues |
| Q90679431 | Antidiabetic therapies and Alzheimer disease |
| Q67002793 | Antihyperglucemic activity of 10 plants in popular use |
| Q47094226 | Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association |
| Q26744208 | Antioxidative and Antidiabetic Effects of Natural Polyphenols and Isoflavones |
| Q76486863 | Apropos of a hypoglycemic coma of sulfonamide origin in a non-diabetic |
| Q36956546 | Are the adverse effects of glitazones linked to induced testosterone deficiency? |
| Q26773423 | Assessment of the Reporting Quality of Placebo-controlled Randomized Trials on the Treatment of Type 2 Diabetes With Traditional Chinese Medicine in Mainland China: A PRISMA-Compliant Systematic Review |
| Q34105156 | Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review |
| Q90193444 | Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients |
| Q90470049 | Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis |
| Q33916532 | Association of the FDA Amendment Act with trial registration, publication, and outcome reporting |
| Q82150686 | Atropine treatment of hypoglycemic fatigue states in soldiers |
| Q125770782 | Audit of glycemic control of diabetic patients on insulin analogues: about 2915 insured persons of the CNAM (Tunisia). |
| Q26827955 | Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes |
| Q38318796 | Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes |
| Q53761645 | B CELL HYPERFUNCTION AFTER LONG-TERM SULFONYLUREA TREATMENT |
| Q76663580 | BIGUANIDES IN THE ORAL THERAPY OF DIABETES MELLITUS |
| Q76872887 | BIOPSY OF THE STOMACH IN THE DIABETIC TREATED WITH HYPOGLYCEMIC DRUGS. COMPARATIVE STUDY |
| Q51691853 | BLOOD LACTIC ACID IN THE FASTING DIABETIC ADULT. STUDY OF ITS VARIATIONS ACCORDING TO THE NATURE AND EFFICACY OF TREATMENT |
| Q76960346 | BRAIN CONCUSSION AND HYPOGLYCEMIC COMA IN A DIABETIC PATIENT |
| Q64239470 | Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment |
| Q28553482 | Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis |
| Q37741752 | Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes |
| Q37145678 | Beta-glucans in the treatment of diabetes and associated cardiovascular risks. |
| Q38597991 | Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL: one-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes |
| Q90555954 | Bi-directional drug-microbiome interactions of anti-diabetics |
| Q27023359 | Biochemical basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes |
| Q55021760 | Biological Activities of Stilbenoids. |
| Q54351581 | Biopharmaceutical Studies on Pyridinolcarbamate. IV. Effect of Continuous Pyridinolcarbamate Administration on Hypoglycemic Activity of Tolbutamide and Chlorpropamide in Rabbits |
| Q26992066 | Biosimilar insulins: guidance for data interpretation by clinicians and users |
| Q46150011 | Blood pressure and type 2 diabetes mellitus: impact of the insulin therapy |
| Q67696348 | Blood sugar lowering effect of various fractions of onion |
| Q64908000 | Body Weight Considerations in the Management of Type 2 Diabetes. |
| Q71490450 | Brittle diabetes. Current treatments and prospects for the future |
| Q33646525 | CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis |
| Q76501597 | CHANGES IN THE POTENCY OF CHLORPROMAZINE AND HYPOGLYCEMIC BIGUANIDES BY COMBINED ADMINISTRATION |
| Q76633534 | CHEMICAL AND PHARMACOLOGICAL RESEARCH ON UREAS WITH HYPOGLYCEMIC ACTION. I. 1-(1,3,4-THIADIAZOL-2-YL)-3-P-TOLUENESULFONYLUREA AND 1-(5-METHYL-1, 3,4-THIADIAZOL-2-YL)-3-P-TOLUENESULFONYLUREA |
| Q76942034 | CHICORY IN MEDICINE |
| Q76600958 | CHRONIC INSULIN-RESISTANT DIABETICS |
| Q76650859 | CLASSIFICATION OF SULFONAMIDES |
| Q76791014 | CLINICAL AND BIOLOGICAL CORRELATIONS IN VASOMOTOR SYMPTOMS INDUCED BY HYPOGLYCEMIA SULFONAMIDES AND ANTABUSE |
| Q76938593 | CLINICAL EFFECTS OF A NEW, POTENT, NON-TOXIC SULFONYLUREA (TOLAZAMIDE) |
| Q76854099 | CLINICAL EVALUATION OF A NEW HYPOGLYCEMIC AGENT WITH CHOLESTEROLEMIC ACTION (TOLAZAMIDE). PRELIMINARY REPORT |
| Q76842240 | CLINICAL EVALUATION OF AN ORAL ANTIDIABETIC CONSISTING OF THE ASSOCIATION OF A SULFONYLUREA AND A BIGUANIDE |
| Q76961636 | CLINICAL EVALUATION OF DRUGS FOR THE TREATMENT OF DIABETES |
| Q78418764 | CLINICAL EVALUATION OF TOLCYCLAMIDE, A HYPOGLYCEMIC AGENT WITHOUT DEMONSTRABLE TOXICITY |
| Q78379763 | CLINICAL EXPERIENCE WITH FICUS BENGALENSIS LINN |
| Q77230934 | CLINICAL EXPERIENCE WITH ORAL THERAPY OF DIABETES MELLITUS |
| Q76847159 | CLINICAL EXPERIENCES WITH A NEW ORAL HYPOGLYCEMIC DRUG, ACETOHEXAMIDE |
| Q76655549 | CLINICAL EXPERIENCES WITH N-N-DIMETHYL-GUANIL-GUANIDINE IN THE MANAGEMENT OF DIABETICS |
| Q76750874 | CLINICAL INVESTIGATION ON THE POSSIBLE TERATOGENIC EFFECTS OF ORAL ANTIDIABETICS ON THE HUMAN FETUS |
| Q76617842 | CLINICAL STUDIES OF THE EFFECTS OF ORAL ANTIDIABETICS IN THE FETUS |
| Q42533925 | CLINICAL STUDIES OF TOLAZAMIDE AND TOLBUTAMIDE: COMPARATIVE EFFECTIVENESS OF CONTROL OF DIABETES MELLITUS |
| Q78360106 | CLINICAL STUDY OF TOLAZAMIDE: A NEW ANTIDIABETIC SULFONYLUREA |
| Q76661481 | CLINICAL TRIAL OF N-N-DIMETHYLBIGUANIDE (DMBG) IN DIABETES MELLITUS |
| Q38525917 | CLINICAL TRIALS IN ELDERLY NORMO- AND HYPERGLYCEMIC PATIENTS WITH A RECENT METHOD OF INSULIN THERAPY: THE PRE-HYPOGLYCEMIC INSULIN THERAPY |
| Q54169386 | CLINICAL TRIALS OF A BIGUANIDE-TOLBUTAMIDE COMBINATION |
| Q76846591 | CLINICAL TRIALS OF ACETOHEXAMIDE, A NEW ORAL ANTIDIABETIC |
| Q76923292 | CLINICAL USE OF PHENFORMIN-CHLORALHYDRATE |
| Q76630886 | CLINICO-STATISTICAL RESEARCH ON DIABETIC RETINOPATHY |
| Q77227478 | COMBINED THERAPY OF DIABETES MELLITUS WITH SULFONAMIDES AND INSULIN |
| Q76709770 | COMMENTARIES ABOUT 107 CONGENITAL MALFORMATIONS |
| Q77151827 | COMPARATIVE RESEARCH ON THE ACTION OF SULFANYLUREAS AND BIGUANIDES ON CARBOHYDRATE METABOLISM IN DIABETICS |
| Q76853835 | COMPARISON OF THE ACTION OF 2 HYPOGLYCEMIC DRUGS ON THE BLOOD SUGAR AND GLUCIDE ASSIMILATION IN THE NORMAL DOG |
| Q78532779 | COMPLICATIONS AND TREATMENT OF DIABETES IN THE AGED |
| Q76931168 | COMPLICATIONS OF THERAPY WITH ORAL HYPOGLYCEMIC AGENTS |
| Q76531718 | CONCERNING THE HYPOGLYCEMIC ACTIVITY OF THE ASSOCIATION OF PHENFORMIN AND CHLORPROPAMIDE IN NORMAL SUBJECTS AND IN PATIENTS WITH DIABETES |
| Q76973449 | CONSIDERATION ON PULMONARY TUBERCULOSIS IN DIABETICS |
| Q78503741 | CONSIDERATIONS ON DIAGNOSIS AND THERAPY OF HYPOGLYCEMIC SYNDROMES |
| Q50160634 | CONSIDERATIONS ON THE POSSIBILITY OF CURING DIABETES MELLITUS. (NOTES ON 3 CASES) |
| Q77117464 | CONTRIBUTION TO EVALUATION OF THERAPY OF PSORIASIS WITH TRIAMCINOLONE, ANABOLIZING DRUGS AND ORAL ANTIDIABETICS |
| Q76596791 | CONTRIBUTION TO THE CLINICAL STUDY OF HYPOGLYCEMIC LANGERHANSIAN EPITHELIOMAS. (APROPOS OF 2 PERSONAL CASES) |
| Q76709003 | CONTRIBUTION TO THE HYPEROSMOLAR, NON-ACIDOTIC COMA IN DIABETES MELLITUS |
| Q76642512 | CONTRIBUTION TO THE PHARMACOLOGICAL STUDY OF BZ 55,HYPOGLYCEMIC SULFAMIDE |
| Q78251455 | CONTRIBUTION TO THE PROBLEM OF DIABETES IN THE AGED |
| Q76793062 | CONTRIBUTION TO THE STUDY OF THE TOXIC EFFECTS DUE TO HYPOGLYCEMIC SULFONYLUREAS |
| Q76940330 | CONTROL OF OBESITY IN DIABETES; A RATIONAL APPROACH |
| Q76847024 | CRITERIA OF EVALUATION OF SULFONAMIDE BLOOD LEVELS DURING ORAL THERAPY OF DIABETES |
| Q76621607 | CRITERIA OF HYPOGLYCEMIC SULFONAMIDE TREATMENT IN DIABETES MELLITUS |
| Q78227710 | CURRENT STATUS OF ANTIDIABETIC BIGUANIDES |
| Q76748101 | CURRENT THERAPEUTICS IN RELATION TO NATURAL REACTIONS. II. APPLICATION TO DIABETES MELLITUS |
| Q35467007 | CURRENT THERAPEUTICS. CCII. ACETOHEXAMIDE |
| Q76499815 | CURRENT TREATMENT OF DIABETES IN ADULTS |
| Q76922342 | CYCLAMIDE (K-386) TREATMENT OF DIABETES MELLITUS |
| Q34388544 | Canagliflozin: a novel treatment option for type 2 diabetes |
| Q35842470 | Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis |
| Q78932778 | Carcinoma of the islets of Langerhans with severe hypoglycemic manifestations in a 9-year-old childsubtotal pancreatectomy |
| Q37361386 | Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review |
| Q28071764 | Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis |
| Q37023878 | Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials |
| Q37412941 | Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies |
| Q26823085 | Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists |
| Q34171759 | Cardiovascular effects of incretin therapy in diabetes care |
| Q26740247 | Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development? |
| Q91527741 | Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus |
| Q37620904 | Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes |
| Q68475991 | Centaurea corcubionensis:A Study of its Hypoglycemic Activity in Rats |
| Q93485443 | Chemistry of salicylic acid and anthranilic acid. III. Hypoglycemic screening tests for salicylic and anthranilic acid derivatives |
| Q36859777 | Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis |
| Q47260574 | Ciclazindol: An oral agent with weight reducing properties and hypoglycaemic activity |
| Q33659194 | Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity |
| Q76461155 | Clinical evaluation of acetohexamide in the treatment of "stable" diabetics |
| Q36097037 | Clinical neuroprotective drugs for treatment and prevention of stroke |
| Q57171958 | Closing the Loop on Managing Youth With Type 1 Diabetes: Children Are Not Just Small Adults |
| Q26741423 | Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects |
| Q53792626 | Coccinia indica Linn. as potential hypoglycaemic agent |
| Q78939396 | Combination of DBI with a sulfonylurea in diabetic therepy |
| Q46087999 | Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus |
| Q36872178 | Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature |
| Q33610749 | Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy |
| Q90915635 | Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine |
| Q27004723 | Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes |
| Q36541464 | Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine |
| Q36835841 | Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease |
| Q24632655 | Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies |
| Q28082405 | Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review |
| Q55235411 | Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials. |
| Q28677533 | Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study |
| Q50766925 | Comparative evaluation of the hypoglycemic effect of ethanol in oral and intravenous administration |
| Q79018265 | Comparative study of the hypoglycemic hormone content of the pineal body in Bovidae |
| Q43407606 | Comparative study with tolbutamide and glibornuride for the diagnosis of latent diabetes mellitus |
| Q35592932 | Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis |
| Q93233974 | Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies |
| Q38645244 | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. |
| Q104793568 | Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications |
| Q33797616 | Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes |
| Q46303576 | Continuous glucose monitoring in glimipiride plus metformin treated type 2 diabetic patients during the month of Ramadan |
| Q37275651 | Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. |
| Q94267734 | Contribution to the study of zygophyllum cornutum (Bou-Griba) new hypoglycemic plant |
| Q78888455 | Control of diabetes mellitus by biguanide (DBI) in childhood |
| Q28078473 | Coronary artery bypass surgery compared with percutaneous coronary interventions in patients with insulin-treated type 2 diabetes mellitus: a systematic review and meta-analysis of 6 randomized controlled trials |
| Q67383042 | Counteraction of glucocorticoid--induced hyperglycaemia by hypoglycin |
| Q34772905 | Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. |
| Q28263149 | Cultivation, Genetic, Ethnopharmacology, Phytochemistry and Pharmacology of Moringa oleifera Leaves: An Overview |
| Q92528383 | Curcumin and Type 2 Diabetes Mellitus: Prevention and Treatment |
| Q81351072 | Current aspects and future perspectives of pharmacotherapy or type II diabetes |
| Q28066006 | Current perspectives on cardiovascular outcome trials in diabetes |
| Q66996251 | Cyclic guanidines. VII. Structure-activity relationships of hypoglycemic cyclic guanidines |
| Q78455444 | DAMAGE DUE TO ANTIDIABETIC TREATMENT |
| Q78907681 | DBI (phenethylidiguanide) in the treatment of diabetes mellitus |
| Q78536253 | DENTITION OF DIABETES. EFFECT OF THE TREATMENT METHODS ON THE NUMBER OF TEETH. II |
| Q78297749 | DETECTION OF ORAL HYPOGLYCEMIC AGENTS IN UINE |
| Q78297745 | DETECTION OF ORAL HYPOGLYCEMIC AGENTS IN URINE |
| Q46825887 | DIABETES IN ASIANS AND AFRICANS IN AND AROUND DURBAN |
| Q76592368 | DIABETES IN THE CAPE PENINSULA |
| Q76825914 | DIABETES MELLITUS AND INFECTIOUS DISEASES |
| Q76565842 | DIABETES MELLITUS: FALLACIES OF ITS DIAGNOSIS AND CURE |
| Q76702188 | DIABETES MELLITUS: ITS DETECTION AND TREATMENT |
| Q76752027 | DIABETIC AMYOTROPHY; A REPORT OF TWO CASES |
| Q76800568 | DIABETIC COMA AND HYPOGLYCEMIC COMA |
| Q76722647 | DIABETIC COMA IN THE 8TH MONTH OF PREGNANCY. THE HAZARDS OF HYPOGLYCEMIC SULFONAMIDES |
| Q76994192 | DIABETIC RESPONSE AND SUCCESSIVE APHASIC EPISODE AFTER MYOCARDIAL INFARCT. CEREBRAL EMBOLISM?HYPOGLYCEMIC SHOCK? |
| Q76815999 | DIAGNOSIS OF DIABETIC NEUROPATHIES. CLINICAL ASPECTS |
| Q76836382 | DIBEIN RETARD IN A CHOSEN GROUP OF DIABETICS |
| Q76798885 | DIET AND DIABETES. (SOME RECENT CONSIDERATIONS) |
| Q76662397 | DISCUSSION ON THE ORAL TREATMENT OF DIABETES MELLITUS |
| Q76812210 | DISTRIBUTION SPACES FOR GLUCOSE, GLUCOSE ANALOGS, ALPHA-AMINO-NITROGEN AND FREE FATTY ACIDS UNDER THE INFLUENCE OF N1-N-BUTYLBIGUANIDE ON EVISCERATED, NEPHRECTOMIZED ANIMALS |
| Q76742273 | DRAMATIC INCIDENTS DURING THE TREATMENT WITH ORAL ANTIDIABETICS |
| Q76793576 | DRUG REACTIONS AFTER INGESTION OF ALCOHOL |
| Q78545248 | DRUG THERAPY OF DIABETES MELLITUS |
| Q76804539 | DRUG-INDUCED LIVER DAMAGE AND COUNTERMEASURES |
| Q76804643 | DRUG-INDUCED THROMBOCYTOPENIA |
| Q84323273 | Dapagliflozin: BMS 512148; BMS-512148 |
| Q27687598 | Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report |
| Q94582014 | Delay of insulin therapy in type 2 diabetics |
| Q49985120 | Depression in Tunisian type 2 diabetic patients: prevalence and association to glycemic control and to treatment compliance |
| Q39664298 | Des 4-trans-hydroxy-glibenclamide show hypoglycemic activity? |
| Q58696993 | Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds |
| Q50126677 | Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. |
| Q46123746 | Diabetes mellitus of elderly patients: therapeutic recommendations |
| Q33843692 | Diabetes, bone and glucose-lowering agents: basic biology |
| Q90224362 | Diabetes: Is There a Future for Pharmacogenomics Guided Treatment? |
| Q64078498 | Diabetes: Oral Health Related Quality of Life and Oral Alterations |
| Q69963717 | Diabetes: current problems |
| Q41993558 | Diabetic Nephropathy: a Tangled Web to Unweave |
| Q73072306 | Diabetic ketosis and ketoacidosis |
| Q28088437 | Diagnosis and management of diabetes and the relationship of dglucose to kidney function |
| Q39285661 | Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention |
| Q47118580 | Dietary Anthocyanins and Insulin Resistance: When Food Becomes a Medicine |
| Q92721967 | Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different |
| Q26765047 | Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies |
| Q27011819 | Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection |
| Q46316311 | Disposal of insulin syringes by diabetic patients. Report of 100 patients |
| Q37577143 | Do GLP-1-based therapies increase cancer risk? |
| Q38178761 | Do incretins improve endothelial function? |
| Q94593412 | Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides |
| Q43664871 | Drug consumption in diabetes mellitus (I). Estimate of the therapeutic profile and the prevalence in the regions of Tarragona (548,900 inhabitants). Grup per a l'Estudi de la Diabetis a Tarragona |
| Q40351532 | Drug information. Agents for the treatment of diabetes mellitus (antidiabetics). Therapeutic maon group: oral antidiabetics |
| Q40450862 | Drug information: slocose. Therapeutic main group: agents for the treatment of diabetes mellitus |
| Q26784192 | Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis |
| Q76576324 | EFFECT OF GLUTAMIC ACID ON THE COURSE OF HYPOGLYCEMIC SHOCK IN RATS WITH REMOVED AND INTACT ADRENALS |
| Q76640136 | EFFECT OF HYPOGLYCEMIC STATES ON THE COURSE OF FIBRINOLYSIS IN MAN |
| Q76504173 | EFFECT OF INSULIN, CHLORPROPAMIDE AND CHLORISOPROPAMIDE ON HOMEOSTATIC FUNCTION OF THE LIVER AND ON PASSAGE OF BLOOD SUGAR INTO THE PORTAL SYSTEM |
| Q77216491 | EFFECT OF PREGNANCY ON DIABETES MELLITUS |
| Q42129649 | EFFECT OF TOLBUTAMIDE ON WEIGHT GAIN, BLOOD SUGAR AND SERUM PROTEINS IN GERIATRIC PATIENTS |
| Q76661109 | EFFECTS OF VARIOUS NATURAL ORGANIC SUBSTANCES AND AMINO ACIDS ON THE BLOOD SURGAR LEVEL AND EXPERIMENTAL STUDIES ON ORAL HYPOGLYCEMIC AGENTS |
| Q78293885 | EVALUATION OF TOLAZAMIDE IN THE TREATMENT OF DIABETES MELLITUS |
| Q76877536 | EXPERIENCE WITH SULFANILAMIDE THERAPY OF DIABETES MELLITUS IN AMBULANT CONDITIONS |
| Q76782065 | EXPERIENCES IN THE USE OF ACETOHEXAMIDE IN DIABETES, AND RESULTS OBTAINED WITH A NEW SIMPLIFIED REAGENT FOR THE DETERMINATION OF GLYCOSURIA |
| Q76789766 | EXPERIENCES WITH PHENFORMIN IN 100 DIABETIC PATIENTS |
| Q78514642 | EXPERIENCES WITH REDUL, A NEW ORAL ANTIDIABETIC |
| Q76948451 | EXPERIMENTAL BASES IN THE PREVENTIVE TREATMENT OF DIABETES |
| Q76860538 | EXPERIMENTAL BASIS FOR COMBINED TREATMENT OF DIABETES WITH THE BIGUANIDE-SULFONAMIDE ASSOCIATION |
| Q35443896 | EXPERIMENTAL DIABETES AND THE MODE OF ACTION OF THE SULFONYLUREAS. WITH SOME SPECULATIONS ON THE PREVENTION OF DIABETES |
| Q51277562 | EXPERIMENTAL STUDIES ON PITUITARY DIABETES. IV. EFFECT OF GYMNEMA SYLVESTRE AND COCCINIA INDICA AGAINST THE HYPERGLYCAEMIC RESPONSE OF SOMATOTROPIN AND CORTICOTROPIN HORMONES |
| Q46257056 | EXPERIMENTAL STUDY OF THE ANTI-ALCOHOL ACTION OF VARIOUS SUBSTANCES |
| Q78314687 | EXPERIMENTAL STUDY OF THE ANTI-ALCOHOL ACTIVITY OF ANIMAL CHARCOAL |
| Q78353752 | EXTRAHEPATIC HYPOGLYCEMIC NEOPLASMS |
| Q33610761 | Early insulin use in type 2 diabetes: what are the cons? |
| Q37577178 | Early insulinization to prevent diabetes progression |
| Q36141300 | Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials |
| Q70923033 | Effect of Momordica charantia on Blood Glucose Level of Normal and Alloxan-Diabetic Rabbits |
| Q88332028 | Effect of Pinocembrin Isolated from Mexican Brown Propolis on Diabetic Nephropathy |
| Q78626103 | Effect of a ganglion-blocking agent on the insulin hypoglycemic curve in the rat |
| Q70968710 | Effect of an extract from the roots of bryony (Bryonia alba) on lipid peroxidation in the liver of rats with alloxan diabetes |
| Q41489963 | Effect of dragon fruit on glycemic control in prediabetes and type 2 diabetes: A systematic review and meta-analysis. |
| Q46585618 | Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review |
| Q39521805 | Effect of heparin, heparin derivatives and heparinoids on blood sugar levels of diabetes mellitus patients |
| Q24628988 | Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials |
| Q26991523 | Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis |
| Q34109435 | Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review |
| Q52579984 | Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. |
| Q28208163 | Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide |
| Q42132473 | Effect of sulfonylurea preparations on the course of pregnancy and the state of the fetuses of female rats with alloxan prediabetes, latent diabetes and mild forms of manifest diabetes |
| Q46686457 | Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. |
| Q33845734 | Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. |
| Q47811538 | Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons |
| Q34124353 | Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials |
| Q27025423 | Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes |
| Q58691975 | Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis |
| Q78990728 | Effects of the simultaneous administration of a corticoid and hypoglycemic sulfonamide in the normal or incompletely depancreatized dog |
| Q52605864 | Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. |
| Q52580579 | Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. |
| Q26782225 | Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus |
| Q28076726 | Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review |
| Q33871367 | Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review |
| Q43087723 | Efficacy of metformin in the treatment of diabetes mellitus complicating thalassemia major |
| Q55000226 | Egg and Soy-Derived Peptides and Hydrolysates: A Review of Their Physiological Actions against Diabetes and Obesity. |
| Q54091211 | Electroencephalographic findings in diabetics with special reference to hypoglycemic conditions |
| Q34502358 | Empagliflozin in the treatment of type 2 diabetes: evidence to date |
| Q57933427 | Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention |
| Q36755942 | Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis |
| Q92313928 | Evaluating Traditional Chinese Medicine and Herbal Products for the Treatment of Gestational Diabetes Mellitus |
| Q91190678 | Evaluation of the Anti-Diabetic Activity of Some Common Herbs and Spices: Providing New Insights with Inverse Virtual Screening |
| Q36877205 | Evolution of exenatide as a diabetes therapeutic |
| Q38245252 | Experimental and clinical evidences for glucose control in intensive care: is infused glucose the key point for study interpretation? |
| Q76476605 | Experimental studies on the mode of action of biguanides |
| Q51691851 | FASTING BLOOD LACTIC ACID, DAILY AND NOCTURNAL LACTIC ACIDURIA OF THE WELL-REGULATED DIABETIC ADULT |
| Q76725842 | FATTY LIVER PATHOGENESIS IN CARASSIUS AURATUS IN GLUCOSE-RICH MEDIUM AND ITS ALTERATION BY N1-N-BUTYLBIGUANIDE AND N'-(4-METHYLBENZOYLSULFONYL)-N'-BUTYLUREA (TOLBUTAMIDE) |
| Q78454860 | FETAL MALFORMATIONS FOLLOWING THE ADMINISTRATION OF ORAL ANTIDIABETICS? |
| Q35467727 | FETAL RESPONSE TO MATERNAL MEDICATION |
| Q76880825 | FOR A NEW TREND IN PHARMACOLOGICAL RESEARCH ON THE EFFECTS OF SULFONAMIDES IN LATE BENIGN DIABETES |
| Q80131678 | Factors influencing homocysteineamia in type 2 diabetic patients |
| Q78534971 | Fatal hypoglycemic coma during chronic histologically confirmed pancreatitis |
| Q37562484 | Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview |
| Q93079853 | Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels |
| Q35705388 | Flavonols in the Prevention of Diabetes-induced Vascular Dysfunction |
| Q26767027 | From obesity to diabetes and cancer: epidemiological links and role of therapies |
| Q37984216 | Fructose might contribute to the hypoglycemic effect of honey. |
| Q76480924 | Functional examination of glycoregulation |
| Q38692092 | Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy |
| Q38667727 | G protein-coupled receptors as new therapeutic targets for type 2 diabetes |
| Q55051694 | GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. |
| Q60044940 | GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data |
| Q33641379 | Gaps and barriers in the control of blood glucose in people with type 2 diabetes. |
| Q89444325 | Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review |
| Q64086698 | Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis |
| Q28255792 | Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis |
| Q34700271 | Glibornuride (Glutril). A new peroral antidiabetic agent |
| Q36251583 | Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected] |
| Q72492676 | Glucagon Immunoreactivity and Antidiabetic Action of Somatostatin in the Totally Duodeno-Pancreatectomized and Gastrectomized Human |
| Q26738580 | Glucagon and heart in type 2 diabetes: new perspectives |
| Q37402786 | Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy |
| Q91979238 | Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features |
| Q28079849 | Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies |
| Q38975192 | Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis |
| Q90901449 | Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development |
| Q36649815 | Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. |
| Q36820255 | Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial |
| Q90912614 | Glutamic Acid Decarboxylase Autoantibody-negative Slowly Progressive Type 1 Diabetes Mellitus: A Case Report and Literature Review |
| Q72368080 | Glybenclamide (HB 419): a new oral antidiabetic agent of the sulfonylurea group |
| Q38219234 | Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials |
| Q26781082 | Glycaemic, blood pressure and cholesterol control in 25 629 diabetics |
| Q24672239 | Glymidine |
| Q76991468 | HAZARDOUS THERAPEUTICS IN THE PREGNANT WOMAN |
| Q76777710 | HISTOCHEMICAL STUDIES ON ADRENAL MEDULLARY CELLS FOLLOWING EXPERIMENTAL ELECTROCONVULSION AND HYPOGLYCEMIC SHOCK |
| Q78251656 | HISTOMORPHOLOGICAL FINDINGS ON THE EXCRETORY SEGMENT OF THE PANCREAS IN RATS AFTER THE EFFECT OF ORAL ANTIDIABETICS |
| Q76655736 | HOW SHOULD THE ANTIDIABETIC SULFONAMIDES BE HANDLED? |
| Q76714100 | HYDROTROPY IN MEDICINE. NEW ETIOPATHOGENIC EMPHASIS OF THE TRIAD OBESITY-ATHEROSCLEROSIS-DIABETES |
| Q76657288 | HYPOGLYCEMIA CAUSED BY HYPOGLYCEMIC DRUGS |
| Q76615030 | HYPOGLYCEMIA IN JUVENILE DIABETES |
| Q76566589 | HYPOGLYCEMIC ACTION OF ACETYLSALICYLIC ACID IN DIABETES IN OLD AGE |
| Q76961294 | HYPOGLYCEMIC ACTION OF INSULIN ON ASSOCIATED HEPATOCYTE AND MYOBLAST CULTURES |
| Q76738845 | HYPOGLYCEMIC ACTION OF KETONES. I. EFFECTS OF KETONES ON HEPATIC GLUCOSE OUTPUT AND PERIPHERAL GLUCOSE UTILIZATION |
| Q76613485 | HYPOGLYCEMIC ACTION OF VASOPRESSIN IN THE ADRENALECTOMIZED OR HYPOPHYSECTOMIZED DOG |
| Q77173774 | HYPOGLYCEMIC ACTION OF VASOPRESSIN IN THE DOG DEPRIVED OF PITUITARY AND PANCREAS (HOUSSAY'S DOG) |
| Q64993433 | HYPOGLYCEMIC ACTIVITY IN RELATION TO CHEMICAL STRUCTURE OF POTENTIAL ORAL ANTIDIABETIC SUBSTANCES. II. ANALOGS OF 1-SULFONYL-3-ALKYLUREAS |
| Q44110947 | HYPOGLYCEMIC COMA AFTER TOLBUTAMIDE |
| Q77001726 | HYPOGLYCEMIC COMA AND HYPERKALEMIC ACIDOSIS AS A SEQUEL TO ALCOHOLIC INTOXICATION |
| Q78315778 | HYPOGLYCEMIC COMA DURING SULFONYLUREA THERAPY |
| Q76514887 | HYPOGLYCEMIC EFFECT OF SULFONYLUREAS (BZ-55,D-860) IN ANIMALS WITH INTERRUPTED CIRCULATION IN THE SPLANCHNIC AREA |
| Q76746776 | HYPOGLYCEMIC ENCEPHALOPATHY TREATED WITH CORTICOSTEROIDS |
| Q76782589 | HYPOGLYCEMIC ENCEPHALOPATHY WITH EPILEPSY. COEXISTENCE OF AN ADENOMA AND DIFFUSE LANGERHANSIAN HYPERPLASIA |
| Q76706738 | HYPOGLYCEMIC REACTION TO LEUCINE, VALINE AND PHENYLALANINE IN A CASE OF DIFFUSE HYPERPLASIA OF THE BETA CELLS |
| Q77098866 | HYPOGLYCEMIC STATES IN DIABETIC CHILDREN |
| Q76719379 | HYPOGLYCEMIC SULFONAMIDES AND ANTABUSE EFFECT |
| Q78504292 | HYPOGLYCEMIC SULFONAMIDES IN COMBINED THERAPY OF DIABETES MELLITUS |
| Q76680001 | HYPOGLYCEMIC SYNDROME DUE TO HYPERFUNCTIONING ISLET CELL ADENOMA |
| Q33150157 | HYPOTENSIVE COLLAPSE AND HYPOGLYCAEMIA AFTER MEBANAZINE--A MONOAMINE-OXIDASE INHIBITOR |
| Q90418580 | Health-Promoting Properties of Selected Cyclitols for Metabolic Syndrome and Diabetes |
| Q33768486 | Healthcare interventions for the prevention and control of gestational diabetes mellitus in China: a scoping review |
| Q36080332 | Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention |
| Q82242777 | Hepatocellular glycogenosis and hepatic neoplasms |
| Q52672986 | Honey and Diabetes: The Importance of Natural Simple Sugars in Diet for Preventing and Treating Different Type of Diabetes. |
| Q37639785 | How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review |
| Q37771436 | How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes |
| Q76481266 | How to treat and control diabetics in current practice |
| Q66924413 | Hydrazonopropionic Acids, a New Class of Non-Hormonal Hypoglycaemic Compounds |
| Q44322750 | Hydrindene Derivatives as Potential oral Hypoglycemic Agents: N-alkyl 1,2,3,3a,4,8b-hexahydroindeno[1,2-b]pyrroles |
| Q79458551 | Hyperlipidaemia associated to inaugurated diabetic ketoacidosis |
| Q70386564 | Hypoglycaemia induced in fasted cats by aqueous extracts of Pithecellobium jiringa |
| Q76490420 | Hypoglycaemic Agents. Part II |
| Q56141988 | Hypoglycaemic action of DIISOpropylammonium salts in experimental diabetes |
| Q67380761 | Hypoglycaemic action of bengalenoside, a glucoside isolated from Ficus bengalensis Linn, in normal and alloxan diabetic rabbits |
| Q67814458 | Hypoglycaemic activity of Acacia catechu, Acacia suma, and Albizzia odoratissima seed diets in normal albino rats |
| Q45366272 | Hypoglycaemic activity of the root bark of Salacia prenoides |
| Q82042623 | Hypoglycaemic coma due to accidental intravenous administration of protamine zinc insulin |
| Q72819960 | Hypoglycaemic effect of Poterium spinosum L. (Rosaceae) |
| Q45946354 | Hypoglycaemic effects of onion, Allium cepa Linn. on diabetes mellitus - a preliminary report |
| Q36783714 | Hypoglycemia and cardiovascular risks |
| Q79012959 | Hypoglycemic Effect of Zea Styles |
| Q70759558 | Hypoglycemic action of Bryonia alba L. unsaturated fatty trihydroxy acids in alloxan diabetes |
| Q40485795 | Hypoglycemic action of chlorella |
| Q71111539 | Hypoglycemic actions of tetrahydroxyquinone, rhodizonic acid and trichinoyl in mice and rabbits |
| Q34581777 | Hypoglycemic activity of Eugenia jambolana and Ficus bengalensis: mechanism of action |
| Q67028284 | Hypoglycemic activity of amine derivatives. A possible mode of action |
| Q43438010 | Hypoglycemic activity of amine derivatives. Preliminary observations |
| Q41622981 | Hypoglycemic activity of aromatic sulfohydrazides and their derivatives |
| Q51647646 | Hypoglycemic activity of l-α-(3,4- dimethoxyphenethylaminomethyl)-2- hydroxybenzylalcohol 12 fumarate (TA-078) in the mouse, rat and dog |
| Q108342577 | Hypoglycemic and Antihyperglycemic effect of Ceiba pentandra L. Gaertn. in normal and streptozotocin-Â?induced diabetic rats |
| Q79073149 | Hypoglycemic attacks due to intrathoracic tumor |
| Q76464012 | Hypoglycemic cardiac arrhythmia in early diabetes mellitus |
| Q74838170 | Hypoglycemic coma during treatment with BZ 55 |
| Q78818640 | Hypoglycemic coma in a diabetic treated with hypoglycemic sulfonamides and reserpine |
| Q77098461 | Hypoglycemic complications after the absorption of pills of the root of a plant from South Tunesia: Bou-Ghriba |
| Q79068196 | Hypoglycemic delirium |
| Q78942750 | Hypoglycemic disease caused by adenoma of islands of Langerhans |
| Q78850475 | Hypoglycemic drugs effective by oral route |
| Q71154764 | Hypoglycemic effect of 3-aza bicyclo 3,3,1 nonanes in rats and rabbits |
| Q82114822 | Hypoglycemic fatigue |
| Q79063271 | Hypoglycemic sulfonamides during pregnancy |
| Q46399704 | IMPORTANCE OF THE VALUE OF ANTIDIABETIC TREATMENT IN PREGNANT DIABETICS |
| Q78530023 | INFLUENCE OF CASTRATION AND ESTROGENS ON THE ACTION OF HYPOGLYCEMIC SULFONAMIDES |
| Q76651874 | INFLUENCING RENAL FUNCTION BY N 1,N-BUTYLBIGUANIDE. I. THE EFFECT ON THE MAXIMAL TUBULAR GLUCOSE RE-ABSORPTION |
| Q76615034 | INSULIN AND ORAL AGENTS: PRINCIPLES IN THE TREATMENT OF DIABETES |
| Q77162310 | ISOLATION OF ORALLY EFFECTIVE HYPOGLYCEMIC COMPOUNDS FROM FICUS BENGALENSIS LINN |
| Q71456520 | Iatrogenic capsuloligamentitis: 3 cases |
| Q48155086 | Identification of barriers to insulin therapy and approaches to overcoming them |
| Q36520655 | Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis |
| Q38645266 | Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes |
| Q38824504 | Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes |
| Q57189952 | Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives |
| Q42382360 | Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme |
| Q38614384 | In Quest for Improved Drugs against Diabetes: The Added Value of X-ray Powder Diffraction Methods |
| Q92529128 | In the Search of Glycoside-Based Molecules as Antidiabetic Agents |
| Q41857384 | In vivo Antidiabetic and Antioxidant Potential of Stephania hernandifolia in Streptozotocin-Induced-Diabetic Rats |
| Q34109320 | In vivo Studies on Antidiabetic Plants Used in South African Herbal Medicine |
| Q41615250 | Inclusion complex of acetohexamide with .BETA.-cyclodextrin and its hypoglycemic activity in rabbit |
| Q26744254 | Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? |
| Q38072203 | Incretin hormones and the satiation signal. |
| Q26778608 | Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors |
| Q26749165 | Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives |
| Q37624267 | Incretin-based therapies: viewpoints on the way to consensus |
| Q43047219 | Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases |
| Q34368524 | Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus |
| Q36596878 | Inhaled insulin for controlling blood glucose in patients with diabetes |
| Q33715395 | Inhaled insulin: overview of a novel route of insulin administration |
| Q78976880 | Inhibition of Ethanol Metabolism by Oral Antidiabetics |
| Q34553759 | Insulin and Glucagon: Partners for Life. |
| Q68321497 | Insulin and oral antidiabetics |
| Q38241834 | Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. |
| Q47721261 | Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes |
| Q36012958 | Insulin detemir in the treatment of type 1 and type 2 diabetes |
| Q36012923 | Insulin glargine in the treatment of type 1 and type 2 diabetes |
| Q37577120 | Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes |
| Q37577175 | Insulin therapy and cancer |
| Q27008886 | Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysis |
| Q26823071 | Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies |
| Q57217641 | Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017 |
| Q34417486 | Insulin therapy in critically ill patients |
| Q38781600 | Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review |
| Q76480222 | Insulin treatment. Mixtures and combinations with hypoglycemic agents |
| Q37017362 | Insulin use in elderly diabetic patients |
| Q24796369 | Insulin: a wonder drug in the critically ill? |
| Q37577153 | Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? |
| Q27001931 | Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy |
| Q66702306 | Interaction between curry ingredient (karela) and drug (chlorpropamide) |
| Q36942266 | Interpreting adverse signals in diabetes drug development programs |
| Q39368850 | Introduction of biosimilar insulins in Europe |
| Q82181125 | Investigations on the new antidiabetic principle (amellin); its role in the reduction of acetone bodies and the increase of alkali reserve of the blood of diabetics |
| Q72050927 | Ionophoretic activity of meglitinide analogues |
| Q36434040 | Is it time for implementation of tight glycaemia control by intensive insulin therapy in every ICU? |
| Q37624301 | Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. |
| Q33610682 | Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes |
| Q38123793 | Is there evidence to support use of premixed or prandial insulin regimens in insulin-naive or previously insulin-treated type 2 diabetic patients? |
| Q76713242 | JAUNDICE DURING ORAL ANTIDIABETIC THERAPY |
| Q92174655 | L-serine: a neglected amino acid with a potential therapeutic role in diabetes |
| Q76717068 | LONG-TERM CHLORPROPAMIDE THERAPY IN DIABETES: FOUR YEARS' EXPERIENCE |
| Q95792506 | Letter: The oral-hypoglycemic controversy |
| Q78594966 | Light post-insulin hypoglycemic state as an analgetic treatment of diseases of the nervous system |
| Q42633492 | Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
| Q36924102 | Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics |
| Q37813419 | Liraglutide in the management of type 2 diabetes |
| Q34180791 | Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability |
| Q37167742 | Long-acting preparations of exenatide |
| Q35044151 | Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. |
| Q60953773 | Looking at Marine-Derived Bioactive Molecules as Upcoming Anti-Diabetic Agents: A Special Emphasis on PTP1B Inhibitors |
| Q46282338 | MANAGEMENT OF DIABETES MELLITUS WITH A NEW MORE ACTIVE, ORAL, HYPOGLYCEMIC AGENT "ACETOHEXAMIDE" |
| Q77066108 | MCQUARRIE TYPE INFANTILE IDIOPATHIC HYPOGLYCEMIA. II. PHYSIOPATHOLOGY OF THE HYPOGLYCEMIC ATTACK |
| Q76676430 | MECHANISM OF ACTION OF ANTIDIABETIC BIGUANIDES |
| Q76650854 | MECHANISM OF ACTION OF HYPOGLYCEMIC SUBSTANCES |
| Q76825879 | MEDICAL TREATMENT OF DIABETES MELLITUS, INCLUDING DIET THERAPY |
| Q76840106 | MEDICAMENTOUS CHOLOSTATIC HEPATITIS |
| Q76805235 | METABOLIC EFFECTS OF THE GAMMA-ETHYLESTER OF 1-GLUTAMIC ACID IN SAKEL'S HYPOGLYCEMIC COMA |
| Q76510293 | MODE OF ACTION OF SOME HYPOGLYCEMIC AGENTS |
| Q76505545 | MODERN ASPECTS OF TREATMENT IN DIABETES. II. ORAL HYPOGLYCEMIC AGENTS VS. INSULIN |
| Q76505546 | MODERN ASPECTS OF TREATMENT IN DIABETES. III. MANAGEMENT OF THE CHILD WITH DIABETES |
| Q64998048 | MODERN DIURETICS AND DIABETES MELLITUS |
| Q77126375 | MORPHOLOGICAL PROBLEMS IN DIABETES RESEARCH |
| Q77054003 | MULTIPLE SCLEROSIS: A NEW APPROACH TO THERAPY |
| Q91517272 | Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence |
| Q55033081 | Management of Inpatient Hyperglycemia and Diabetes in Older Adults. |
| Q26766259 | Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control |
| Q38756971 | Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer. |
| Q37617500 | Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations |
| Q33630122 | Mangiferin: a natural miracle bioactive compound against lifestyle related disorders |
| Q28073250 | Marine Organisms with Anti-Diabetes Properties |
| Q27014826 | Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus |
| Q67055709 | Mechanism of the antidiabetic effect of cysteine |
| Q42374458 | Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis |
| Q90301380 | Mechanisms of action of metformin with special reference to cardiovascular protection |
| Q24642503 | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes |
| Q78846513 | Mesotheliomas and extraovarian thecomas with hypoglycemic and nephrotic syndromes |
| Q33672932 | Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients |
| Q59138235 | Metabolic Effects of Metformin in the Failing Heart |
| Q36012896 | Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes |
| Q38673914 | Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla |
| Q36300318 | Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis |
| Q26765139 | Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis |
| Q28077202 | Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q58699189 | Metformin and blood cancers |
| Q38999875 | Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation |
| Q35645149 | Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer |
| Q26999266 | Metformin and the risk of cancer: time-related biases in observational studies |
| Q45971464 | Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome |
| Q34424886 | Metformin for aging and cancer prevention |
| Q28480735 | Metformin in obesity, cancer and aging: addressing controversies |
| Q64083675 | Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management |
| Q33648824 | Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis |
| Q26850912 | Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review |
| Q28072501 | Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis |
| Q26738743 | Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis |
| Q38647784 | Metformin use in pregnancy: promises and uncertainties. |
| Q41545473 | Metformin: a review of its potential indications |
| Q39993625 | Microbial Metabolites as Potentially useful Pharmacologically active Agents |
| Q76460562 | Mixed therapy of diabetes |
| Q51677722 | Mode of action of oral antidiabetic drugs |
| Q26771754 | Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers |
| Q36516516 | Modulating gut microbiota as an anti-diabetic mechanism of berberine. |
| Q55284911 | Molecular Mechanisms Underlying Curcumin-Mediated Therapeutic Effects in Type 2 Diabetes and Cancer. |
| Q26752387 | Molecular Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids |
| Q47123503 | Monotherapy in patients with type 2 diabetes mellitus. |
| Q26998824 | Monounsaturated fatty acids and risk of cardiovascular disease: synopsis of the evidence available from systematic reviews and meta-analyses |
| Q38599441 | Multiple therapeutic effect of endothelial progenitor cell regulated by drugs in diabetes and diabetes related disorder. |
| Q91254738 | Mushrooms of the Genus Ganoderma Used to Treat Diabetes and Insulin Resistance |
| Q92313815 | Myoinositol in the Prevention of Gestational Diabetes Mellitus: Is It Sensible? |
| Q64065007 | Myths about Insulin Resistance: Tribute to Gerald Reaven |
| Q78493682 | NEW PHARMACOLOGIC PRODUCTS. 2. BUFORMIN FOR ORAL THERAPY OF DIABETES |
| Q77077863 | NEWER PERSPECTIVES IN DIABETES WITH COMMENTS ON SYNTHETIC INSULIN AND ORAL AGENTS |
| Q76842625 | NON-ESTERIFIED FATTY ACIDS IN CLINICAL PRACTICE. DIABETES |
| Q26786307 | Neuropharmacological Actions of Metformin in Stroke |
| Q58773068 | Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease |
| Q47113843 | New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. |
| Q57189954 | New clinical trial designs for establishing drug efficacy and safety in a precision medicine era |
| Q64912183 | New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. |
| Q59812400 | New hypoglycemic agents and the kidney: what do the major trials tell us? |
| Q37240506 | New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes |
| Q72337350 | New synthesis of sulphonylureas |
| Q72395990 | Notes. Thiomethyltetrazole Hypoglycemic Agents |
| Q64240263 | Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways |
| Q37673171 | Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users. |
| Q35434820 | OBSERVATIONS ON THE ETIOLOGY AND THERAPY OF "BRITTLE" DIABETES |
| Q78562197 | OBSERVATIONS ON THERAPY WITH ORAL ANTIDIABETICS IN ACUTE DIABETES |
| Q76811455 | OBSTETRICAL RESULTS IN 90 PREGNANCIES WITH DIABETOID STATE |
| Q76895013 | ON A RARE CASE, IN A CHILD OF 4 YEARS, OF HYPOGLYCEMIC COMA DUE TO ABSORPTION OF DENATURED ALCOHOL THROUGH SKIN DAMAGED BY A RECENT BURNING |
| Q76828974 | ON DOCUMENTING THE TREATMENT OF HYPOGLYCEMIC COMA |
| Q77143028 | ON HYPOGLYCEMIC ENCEPHALOPATHY |
| Q78430224 | ON SIDE-EFFECTS OF SULFONYLUREAL PREPARATIONS ON THE BLOOD PICTURE |
| Q76898185 | ON THE ACTION OF SULFANYLUREAS ON THE ISLANDS OF LANGERHANS |
| Q78364251 | ON THE ASSOCIATION OF PULMONARY TUBERCULOSIS AND DIABETES MELLITUS. RESULTS OBTAINED ADMINISTERING TO THESE PATIENTS AN ORAL ANTIDIABETIC |
| Q78393251 | ON THE CLINICAL ADJUSTABILITY OF VARIOUS FORMS OF DIABETES IN DELAYED-ACTION INSULIN THERAPY, COMBINED AND EXCLUSIVELY ORAL THERAPY WITH SULFONYLUREA DERIVATIVES AND BIGUANIDES |
| Q76531660 | ON THE COMBINATION OF SULFONYLUREA AND BIGUANIDE IN SMALL DOSES IN THE THERAPY OF DIABETES MELLITUS |
| Q77075348 | ON THE EFFECT OF N1,N-BUTYLBIGUANIDE ON RENAL FUNCTION. II. CHANGES IN INULIN- AND PAH-CLEARANCE |
| Q78407169 | ON THE EFFECT OF REDUL AND TRENIMON AND FRUCTOSE-1,6-DIPHOSPHATASE ON EHRLICH ASCITES TUMOR CELLS. I. THE EFFECT OF REDUL ALONE AND IN COMBINATION WITH TRENIMON ON EHRLICH ASCITES TUMOR |
| Q76816439 | ON THE HYPOGLYCEMIC ACTION OF ALCOHOL. A STUDY OF AGED SUBJECTS |
| Q76898409 | ON THE HYPOGLYCEMIC AND INSULIN-POTENTIATING EFFECT OF METHAHEXAMINE |
| Q78550568 | ON THE MECHANISM OF ACTION OF BIGUANIDE |
| Q76866024 | ON THE PRESENCE OF AN ANTIDIABETIC PRINCIPLE IN MOMORDICA CHARANTIA |
| Q78271440 | ON THE PROBLEM OF LIMITED EFFECTIVENESS OF SULFONYLUREA THERAPY IN DIABETES MELLITUS |
| Q78401253 | ON THE THERAPY AND PROGNOSIS OF DIABETES MELLITUS IN CHILDHOOD |
| Q76723903 | ON THE TREATMENT OF DIABETES MELLITUS WITH GUANIDINE DERIVATIVES |
| Q76879085 | ON TOLAZAMIDE: APROPOS OF A NEW HYPOGLYCEMIC SULFANYLUREA AND OF ACQUIRED SULFANYLUREAU RESISTANCE |
| Q76809755 | ORAL ANTIDIABETICS |
| Q76864970 | ORAL DIABETES THERAPY |
| Q35453399 | ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF DIABETES MELLITUS |
| Q42496380 | ORAL HYPOGLYCEMIC DRUGS |
| Q76890879 | ORAL HYPOGLYCEMIC DRUGS: COMPARATIVE EVALUATION OF TOLBUTAMIDE, CHLORPROPAMIDE AND PHENFORMIN |
| Q78497797 | ORAL THERAPY FOR DIABETES MELLITUS |
| Q78401818 | ORAL THERAPY OF DIABETES |
| Q76789724 | ORAL THERAPY OF DIABETES MELLITUS |
| Q76857070 | ORAL THERAPY OF DIABETES WITH SULFONYLUREA DERIVATIVES |
| Q38526111 | ORAL TREATMENT OF DIABETES BY PHENBUTAMIDE. (RESULTS IN 20 CASES) |
| Q76952596 | ORAL TREATMENT OF DIABETES WITH ACETOHEXAMIDE |
| Q77230064 | ORAL TREATMENT OF DIABETES WITH GLYCODIASIN |
| Q76919946 | OUR EXPERIENCES IN THE TREATMENT OF DIABETICS WITH BUTYLBIGUANIDE |
| Q76975820 | OUR EXPERIENCES WITH ORAL ANTIDIABETICS IN OUTPATIENT CONTROL AND TREATMENT OF DIABETIC PATIENTS |
| Q37972071 | Oligosaccharides might contribute to the antidiabetic effect of honey: a review of the literature. |
| Q37717838 | On the potential of acarbose to reduce cardiovascular disease |
| Q76485279 | On the problem of the control of diabetes mellitus with hyaluronic acid |
| Q78781673 | On the question of the form of application of oral antidiabetics |
| Q78806461 | On the recognition of drug exanthem caused by oral antidiabetics |
| Q72278224 | On the significance of the glucose tolerance test in comparison with the sulfonylurea test |
| Q26858961 | Optimal glycemic control in neurocritical care patients: a systematic review and meta-analysis |
| Q38213126 | Optimal utilisation of sulphonylureas in resource-constrained settings |
| Q90897913 | Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes |
| Q72864952 | Oral anti diabetic drugs |
| Q44266731 | Oral antidiabetics 1977 |
| Q76489999 | Oral hypoglycemic agents in diabetics with gastrointestinal diseases |
| Q67595639 | Oral hypoglycemics: what you and your patient need to know |
| Q76460701 | Oral medication of diabetes mellitus |
| Q78861853 | Oral therapy of diabetes with K 386 ("Agliral") |
| Q78823181 | Orally active hypoglycemic substances and the rationale of their use |
| Q53845844 | PANEL DISCUSSION: DIABETES MELLITUS AND RELATED SUBJECTS |
| Q78551030 | PATHOGENESIS AND CLINICAL IMPORTANCE OF THE HYPOGLYCEMIC SYNDROME IN THE NEWBORN |
| Q76789365 | PERORAL TREATMENT OF DIABETES MELLITUS |
| Q76848586 | PHENFORMIN IN WEIGHT REDUCTION OF OBESE DIABETICS |
| Q52763376 | PHOTODERMATITIS INDUCED BY DRUGS. II. PHOTODERMATITIS MEDICAMENTOSA |
| Q35465821 | PHOTOSENSITIZATION DUE TO DRUGS: A REVIEW OF SOME OF THE RECENT LITERATURE |
| Q35466226 | PHYSIOLOGY AND PHARMACOLOGY OF FIBRINOLYSIS |
| Q76646775 | POLYTHIAZIDE (RENESE), A THIAZIDE PREPARATION WITH ONLY A SLIGHT DIABETOGENIC EFFECT |
| Q76569164 | POSSIBLE NON-DIABETIC EFFECTS OF SULFONYLUREA |
| Q78383903 | POSTOPERATIVE HYPOGLYCEMIC COMA |
| Q54936265 | PPAR Agonists and Metabolic Syndrome: An Established Role? |
| Q35458969 | PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. |
| Q37857704 | PPARγ agonist beyond glucose lowering effect. |
| Q76890429 | PREDIABETES AND THE EFFECT OF SULPHONYLUREA IN ITS TREATMENT |
| Q76689312 | PREDIABETES. DEFINITION, DIAGNOSIS AND TREATMENT |
| Q78478816 | PREGNANCY COMPLICATED BY DIABETES. REPORT OF 102 PREGNANCIES INCLUDING ELEVEN TREATED WITH ORAL HYPOGLYCEMIC DRUGS |
| Q78393731 | PRINCIPLES IN THE USE OF INSULIN AND ORAL AGENTS IN THE TREATMENT OF DIABETES |
| Q78406558 | PROBLEMS OF LATE FAILURE OF ORAL SULFONYLUREA THERAPY OF DIABETES |
| Q76629285 | PRODUCTION OF MALFORMATIONS IN THE MOUSE AND RABBIT BY ADMINISTRATION OF A HYPOGLYCEMIC SULFONAMIDE, CARBUTAMIDE |
| Q78274303 | PROGNOSIS IN TUBERCULOSIS IN DIABETIC PATIENTS |
| Q76664075 | PROLONGED HYPOGLYCEMIC COMA AND IRREVERSIBLE CEREBRAL CAUSED BY ADMINISTRATION OF CHLORPROPAMIDE IN A NON-DIABETIC PATIENT |
| Q77155125 | PROLONGED SUPPORTIVE SULFONAMIDE THERAPY OF DIABETIC PATIENTS |
| Q52638299 | PROLONGED THERAPEUTIC USE IN FRACTIONATED DOSES OF A SYNTHETIC ANTI-ADRENAL SUBSTANCE(OP'D.D.D.) |
| Q36536316 | PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. |
| Q76674553 | PULMONARY TUBERCULOSIS IN DIABETICS AND PARADIABETICS: FAILURE OF PREVENTION AND THERAPEUTIC TRENDS |
| Q51692233 | PYRUVATE-TOLERANCE TESTS IN HEALTHY AND DIABETIC SUBJECTS |
| Q68851389 | Pancreatitis and diabetes |
| Q39349756 | Past and current perspective on new therapeutic targets for Type-II diabetes. |
| Q38188871 | Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes |
| Q33793790 | Patient preferences for noninsulin diabetes medications: a systematic review |
| Q91086010 | Perioperative Management of the Diabetic Patient Referred to Cardiac Surgery |
| Q44375057 | Peroral antidiabetic agents--shall we stop using these drugs? |
| Q36812788 | Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives |
| Q26775259 | Personalized medicine in diabetes: the role of 'omics' and biomarkers |
| Q37508445 | Pharmacogenetics and personalized treatment of type 2 diabetes |
| Q90267161 | Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine |
| Q26749524 | Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations |
| Q44215438 | Pharmacokinetic behaviour of gliquidone (AR-DF 26), a new sulfonyl urea. Summary of the studies so far (author's transl) |
| Q53739870 | Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic |
| Q51664142 | Pharmacologic profile of methyl 2-tetradecylglycidate (McN-3716)--an orally effective hypoglycemic agent |
| Q92475652 | Pharmacological Treatment for Non-alcoholic Fatty Liver Disease |
| Q70947755 | Pharmacological sequential trials for the fractionation of components with hypoglycemic activity in alloxan diabetic mice from ginseng radix |
| Q93119965 | Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK |
| Q71179305 | Pharmacotherapeutic reviews. XXII. Insulin and oral antidiabetics |
| Q39064669 | Phlorotannins: Towards New Pharmacological Interventions for Diabetes Mellitus Type 2. |
| Q72279739 | Phosphorus Analogs of Sulfonylureas. Sodium N-Carbamoylphosphonamidates |
| Q43148344 | Photosensitivity induced by metformin: a report of 3 cases |
| Q37643472 | Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus - current status |
| Q89224473 | Phytochemicals: Target-Based Therapeutic Strategies for Diabetic Retinopathy |
| Q47210608 | Phytotherapy in the Management of Diabetes: A Review. |
| Q70521123 | Pill Abuse and Hypoglycemia |
| Q34139048 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment |
| Q37576689 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis |
| Q35987456 | Pioglitazone and sulfonylureas: effectively treating type 2 diabetes |
| Q44599720 | Plant hypoglycemic agents |
| Q42797527 | Poglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism |
| Q108162977 | Possible role of trace elements in the hypoglycemic effect of plants extract in diabetic rats |
| Q50054523 | Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines |
| Q26865976 | Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide |
| Q26797339 | Potential Bioactive Compounds from Seaweed for Diabetes Management |
| Q33604118 | Potential of Lichen Compounds as Antidiabetic Agents with Antioxidative Properties: A Review |
| Q37479037 | Potential of liraglutide in the treatment of patients with type 2 diabetes. |
| Q26827101 | Potential roles of GPR120 and its agonists in the management of diabetes |
| Q33621582 | Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management |
| Q36012965 | Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes |
| Q37193917 | Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk |
| Q57189955 | Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations |
| Q72798928 | Preparation of Tritium-Labeled Compounds I. Series of Sulfonylurea Hypoglycemic Agents by Exchange with Tritium Gas |
| Q28084768 | Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies |
| Q36748541 | Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods |
| Q76480218 | Problems in ambulant diabetes therapy |
| Q38542019 | Productivity of authors in the field of diabetes: bibliographic analysis of trial publications |
| Q64228172 | Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy |
| Q89994744 | Protein Kinase CK2-A Putative Target for the Therapy of Diabetes Mellitus? |
| Q78931728 | Purification and properties of a hypoglycaemic peptide from ox growth hormone |
| Q66932494 | QSAR studies in a series of new hypoglycemic sulphonamides |
| Q76693712 | QUANTITATIVE STUDY OF NEOGENESIS OF THE ISLANDS OF LANGERHANS OF THE PANCREAS INDUCED BY A HYPOGLYCEMIC SULFONAMIDE, TOLBUTAMIDE |
| Q71540251 | Quaternary indolylpyridinium salts. Oral hypoglycemic agents |
| Q77001556 | RECENT ADVANCES AND TRENDS IN DRUG THERAPY. IV. ORAL HYPOGLYCAEMIC AGENTS |
| Q76947578 | RECURRENT UMBILICAL COLICS IN DIABETES MELLITUS OF CHILDHOOD. A RARE MANIFESTATION OF HYPOGLYCAEMIC BRAIN DAMAGE |
| Q46631827 | REMARKS APROPOS OF THE BIGUANIDE-HYPOGLYCEMIC SULFONAMIDE COMBINATION IN PHARMACOLOGY AND CLINICAL PRACTICE |
| Q78376177 | REMISSION OF DIABETES AND PRE-HYPOGLYCEMIC INSULIN THERAPY |
| Q76952212 | RENAL COMPLICATIONS IN DIABETES |
| Q76828696 | RESEARCH ON THE EXTRARENAL ACTION OF NEUROHYPOPHYSIAL SECRETION. HYPOGLYCEMIC ACTION OF ANTIDIURETIC HORMONE AFTER HYPOPHYSECTOMY OR ADRENALECTOMY IN DOGS |
| Q76966433 | RESEARCH ON THE MECHANISM OF ACTION OF DIMETHYLBIGUANIDE ON GLUCOSE METABOLISM IN RATS WITH ALLOXAN DIABETES |
| Q76915329 | RESPECTIVE ACTIONS OF 3 HYPOGLYCEMIC THIADIAZOLOSULFONAMIDES ON THE BLOOD SUGAR OF THE NONANESTHETIZED DOG |
| Q76917036 | RESULTS OF THE TREATMENT OF DIABETES WITH N.N. DIMETHYL-BIGUANIDE. APROPOS OF 40 CASES |
| Q76592377 | RETINOPATHY IN WOMEN OVER 45 YEARS OF AGE ATTENDING A DIABETES CLINIC, INCLUDING ITS RELATIONSHIP TO THERAPY WITH SULPHONYLUREAS |
| Q92925692 | Recent advances in diabetes treatments and their perioperative implications |
| Q53913491 | Recent contributions concerning the hypoglycemic activity of "Zygophyllum cornutum" (Bou-Ghriba) |
| Q31121925 | Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes |
| Q37167551 | Redefining the role of thiazolidinediones in the management of type 2 diabetes |
| Q37939075 | Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis |
| Q52193394 | Reflex differences in hypoglycemic schizophrenics with a few remarks on the possible role of the right hemisphere in the production of some mental symptoms |
| Q78889264 | Relations between the hypoglycemic and diuretic action of chlorpromazine and chlorothiazide |
| Q71098749 | Relationship between Hypoglycemic Activity and Binding Ability with Bovine Serum Albumin of Sulfonylurea Related Compounds |
| Q41446588 | Relationship between structure and hypoglycemic activity in a series of amide substituted p-N-R-sulfamidooxanilic acids |
| Q92695551 | Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus |
| Q33789329 | Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease |
| Q67392003 | Resistance to hypoglycemic sulfanilamides and biguanidines and its immune genesis |
| Q76486093 | Results of long term treatment with 1 600 S and 1 610 S of adult diabetes. (Apropos of 58 cases) |
| Q58703762 | Resveratrol Counteracts Insulin Resistance-Potential Role of the Circulation |
| Q55288083 | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice. |
| Q39345916 | Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus |
| Q37058917 | Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes |
| Q91984454 | Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects |
| Q37340223 | Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists |
| Q36290660 | Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries |
| Q38954092 | Review: Traumatic brain injury and hyperglycemia, a potentially modifiable risk factor |
| Q36013099 | Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination |
| Q47164210 | SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials |
| Q76646000 | SENILE DIABETES |
| Q78532867 | SENILE DIABETES. SOME CONSIDERATIONS OF CLINICAL INTEREST |
| Q76996348 | SEROTONIN AND PSYCHIATRY |
| Q76510410 | SERUM INSULIN-LIKE ACTIVITY AND THE EFFECT OF ORAL ANTI-DIABETIC DRUGS WITH SPECIAL REFERENCE TO FAILURE IN LONG-TERM USE |
| Q78417166 | SEVERE HYPOGLYCEMIA IN DIABETICS TREATED WITH HYPOGLYCEMIC SULFONAMIDES (APROPOS OF 3 CASES) |
| Q76506082 | SEVERE HYPOGLYCEMIC MANIFESTATIONS IN TUBERCULOUS DIABETICS TREATED WITH ETHIONAMIDE |
| Q58718282 | SGLT inhibitor adjunct therapy in type 1 diabetes |
| Q26746901 | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives |
| Q76960252 | SIDE-EFFECTS IN THE ORAL TREATMENT OF DIABETES WITH SULFONYLUREAS |
| Q35431588 | SOME ASPECTS OF DERMATOLOGY IN DIABETES MELLITUS. A REVIEW OF SOME RECENT LITERATURE |
| Q76565832 | SOME PROBLEMS OF DIABETES |
| Q77175381 | STUDIES ON HYPOGLYCEMIC AGENTS. 3. SYNTHESIS OF 2H-1,2,4-BENZOTHIADIAZIN-3(4H)-ONE 1,1-DIOXIDES |
| Q77175377 | STUDIES ON HYPOGLYCEMIC AGENTS. II. SYNTHESIS OF 1-ACYL-4-SULFONYLSEMICARBAZIDES AND 1-SULFONYL BIUREAS |
| Q77091507 | STUDIES ON THE HYPOGLYCEMIC ACTIVITY OF THE MEDICAL HERBS |
| Q76843775 | STUDIES ON THE MODE OF ACTION OF HYPOGLYCEMIC BIGUANIDES |
| Q76643892 | STUDIES ON THE PANCREAS IN WHITE MICE. VI. ON THE EFFECT OF N1-N-BUTYL-BIGUANIDE ON THE GRANULE AND NUCLEAR VOLUME OF BETA CELLS |
| Q53749807 | STUDIES ON THE PROBLEM OF THE SO-CALLED LATE FAILURE OF SULFONYLUREA THERAPY |
| Q76717181 | STUDY OF THE MECHANISM OF ACTION OF GUANIDINE DERIVATIVES |
| Q78486917 | STUDY OF THE MODE OF EXCRETION OF N,N-DIMETHYLBIGUANIDE IN AN ADULT DIABETIC |
| Q78382321 | SULFONAMIDE BULLOUS ERYTHEMA SIMULATING STEVENS-JOHNSON DISEASE |
| Q76975677 | SURVIVAL OF THE PATIENT WITH DIABETES MELLITUS IN A THERMONUCLEAR WAR |
| Q78563785 | SYNTHESIS OF AZOLIDINE DERIVATIVES CONTAINING POSSIBLE HYPOGLYCEMIC ACTIVITY. 3. SULFACYL DERIVATIVES OF PSEUDOTHIOHYDANTOIN |
| Q76940795 | SYNTHETIC DRUGS AND NATURAL SUBSTANCES AS DRUGS. (ADVANCES IN 1962) |
| Q76657951 | SYNTHETIC HYPOGLYCEMIC AGENTS AND PREGNANCY |
| Q91535203 | Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA) |
| Q34767965 | Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis |
| Q28078467 | Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis |
| Q34606070 | Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes |
| Q37202144 | Safety and efficacy of rosiglitazone in the elderly diabetic patient |
| Q34349437 | Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis |
| Q91305901 | Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease |
| Q36477828 | Self-monitoring of blood glucose in noninsulin-using type 2 diabetic patients: it is time to face the evidence |
| Q33892377 | Serum lactate level and mortality in metformin-associated lactic acidosis requiring renal replacement therapy: a systematic review of case reports and case series |
| Q70848822 | Should prescription of oral hypoglycemies be continued? A social pharmacology problem. Experience of the diabetes outpatient clinic of the Sousse C.H.U |
| Q46254647 | Some observations upon 4,000 African and Asiatic diabetics collected in Durban between 1958 and 1962 |
| Q28341914 | Species-Specific Hypoglycemic Activity of Triphenylphosphoranylideneacetophenones |
| Q42373168 | Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date |
| Q70620601 | Stability of Tecomine, the Major Antidiabetic Factor of Tecoma Stans (Juss.) f. Bignoniaceae |
| Q36670318 | Stepwise intensification of insulin therapy in type 2 diabetes management--exploring the concept of the basal-plus approach in clinical practice |
| Q37702216 | Stroke and diabetic ketoacidosis--some diagnostic and therapeutic considerations. |
| Q79033218 | Studies on sulfonylurea derivates. I. Synthesis and hypoglycemic action of sulfonylureas |
| Q47779112 | Studies on the anti-diabetic effects of Casearia esculenta |
| Q39176138 | Studies on the hypoglycaemic action of gliclazide, a sulphonyl-urea drug [proceedings] |
| Q44221429 | Studies on the mechanism of centpiperalone-induced hypoglycemia |
| Q42142599 | Studies on the pharmacokinetics of antidiabetic biduanide salts with depot effectiveness (proceedings) |
| Q52193452 | Studies regarding glutamine and ammonia in the cerebrospinal fluid of patients with nervous and mental diseases (with some observations on insulin hypoglycemic shock and oligophrenia phenylpyruvica) |
| Q78880955 | Study on the absence of antibacterial properties in a new synthetic antidiabetic, 1-(3-aminobenzenesulfonyl)-3-n-butylurea or SB 1 |
| Q72781114 | Sulfamylsemicarbazide Hypoglycemic Agents. IV |
| Q76482479 | Sulfonylurea derivatives in the treatment of some parenchymal lesions of the liver |
| Q76461157 | Sulfonylureas: their clinical limitations and rational use in the treatment of diabetes |
| Q78834260 | Symposium on “A New Oral Hypoglycemic Agent, Phenformin (DBI)”: General Summary |
| Q67356892 | Synthesis and Biological Evaluation of Potential Hypoglycemic Agents I: Carnitine Analogs |
| Q70590184 | Synthesis and hypoglycemic activity of 3-aryl(or pyridyl)-5-alkyl(or aryl)amino-1,3,4-thiadiazoles and some sulfonylurea derivatives of 4H-1,2,4-triazoles |
| Q54207885 | Synthesis and hypoglycemic activity of substituted alkyl- and alkoxyguanidines |
| Q72705677 | Synthesis of Potential Antidiabetic Agents. 1-p-Tolylsulfonyl-2-benzimidazolinones and 1-p-Tolylsulfonyl-2-benzimidazolinethiones |
| Q70679958 | Synthesis of azolidin derivatives with a possible hypoglycemic effect. 8. Aminomethylation of azolidin derivatives and their possible hypoglycemic action |
| Q79051548 | Synthesisand Hypoglycemic Activity of Trifluoromethylated Sulphonylureas |
| Q36136847 | Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma |
| Q76559880 | THE 2 TYPES OF DIABETES |
| Q78472043 | THE ACTION OF ORAL HYPOGLYCEMIC AGENTS |
| Q35456508 | THE ACTION OF SULFONYLUREAS IN PRODUCING HYPOGLYCEMIA |
| Q76828317 | THE APPLICATION OF CYBERNETIC METHODS IN THE DIAGNOSIS AND TREATMENT OF DIABETES |
| Q76970667 | THE EFFECT OF N1-N-BUTYLBIGUANIDE ON OXYGEN AND GLUCOSE CONSUMPTION BY THE AORTA OF ALLOXAN DIABETIC RATS |
| Q78428777 | THE EFFECT OF SULPHONYL UREA DERIVATIVES ON THE HEALTHY AND ON THE DISEASED LIVER |
| Q34812792 | THE EFFECTS OF DEXTROTHYROXINE IN DIABETES |
| Q76687295 | THE HAZARDS OF DRUG THERAPY IN THE PREGNANT WOMAN |
| Q33355624 | THE HEMATOLOGICAL RISK IN TREATMENT WITH HYPOCLYCEMIC SULFONAMIDES |
| Q76574341 | THE HYPOGLYCAEMIC EFFECT OF AZACYCLONOL AND ITS MECHANISM |
| Q76665812 | THE HYPOGLYCEMIC ACTIVITY OF BLOOD PLASMA OF NORMAL AND DIABETIC SUBJECTS IN BASAL CONDITIONS AND IN OVERLOAD |
| Q76659194 | THE HYPOGLYCEMIC SYNDROME. FORENSIC-PSYCHIATRIC AND PSYCHOPATHOLOGIC CONTRIBUTION |
| Q76669710 | THE INFLUENCE OF PLASMA UPON THE GLUCOSE UPTAKE OF ERYTHROCYTES IN VARIOUS DISEASES WITH GLYCOSURIA. 2. CHANGES IN THE INFLUENCE OF PLASMA UPON THE GLUCOSE UPTAKE OF ERYTHROCYTES IN TREATED DIABETES MELLITUS |
| Q46265878 | THE INFLUENCE OF THE CONSTITUENTS OF THE LYTIC COCKTAIL ON THE ACTION OF HYPOGLYCEMIC AGENTS |
| Q76624026 | THE LIVER IN DIABETES |
| Q76622785 | THE MANAGEMENT OF DIABETES MELLITUS IN HOMES FOR THE AGED |
| Q77216485 | THE MECHANISM OF ACTION OF PERORAL ANTIDIABETICS |
| Q34255871 | THE MODERN MANAGEMENT OF DIABETES MELLITUS |
| Q77164399 | THE NEW DRUGS RELEASED DURING 1963 AND 1964 |
| Q78558293 | THE ORAL HYPOGLYCEMIZING AGENTS IN DIABETES MELLITUS. OBSERVATIONS AND RESERVES |
| Q76659934 | THE PLACE OF LEFT PANCREATECTOMY IN THE TREATMENT OF HYPOGLYCEMIC ATTACKS CAUSED BY LANGERHANSIAN ADENOMAS |
| Q76791009 | THE POLYMORPHOUS PAINFUL SYNDROME OF THE LOWER EXTREMITIES IN DIABETES |
| Q78426427 | THE PRESCRIPTION OF ORAL ANTIDIABETICS |
| Q77071024 | THE PROBLEM OF DIABETES |
| Q54714666 | THE PROBLEM OF DIABETES: PREDIABETES, ABNORMAL MINIMUM AND ABNORMAL MAXIMUM INSULIN REQUIREMENTS, ORAL ANTIDIABETICS |
| Q76804066 | THE PROBLEM OF JAUNDICE |
| Q77073753 | THE PRODUCT OF KETONE BODIES IN SAKEL'S HYPOGLYCEMIC COMA |
| Q76714606 | THE PROTECTIVE EFFECT OF ANTIDIABETIC SULFOCARBAMIDES IN THE LIVER |
| Q76682264 | THE ROLE OF ORAL ANTIDIABETICS AS ACTIVATORS IN EPILEPSY |
| Q76511089 | THE SECONDARY EFFECTS OF MODERN MEDICAMENTS |
| Q76743084 | THE THERAPY OF DIABETES MELLITUS |
| Q78376114 | THE TOLBUTAMIDE TEST IN DIABETICS TREATED WITH PRE-HYPOGLYCEMIC INSULIN THERAPY |
| Q76813271 | THE TREATMENT OF DIABETES APPEARING AFTER THE AGE OF 50 |
| Q76671367 | THE TREATMENT OF DIABETES IN ADULTS WITH N-N-DIMETHYLBIGUANIDE |
| Q78488030 | THE TREATMENT OF DIABETIC PATIENTS WITH GLYCODIAZINE (GONDAFON) |
| Q78244930 | THE USE OF ACETOHEXAMIDE IN THE TREATMENT OF DIABETES MELLITUS |
| Q76781128 | THE USE OF PHENFORMIN IN TREATMENT OF DIABETES MELLITUS |
| Q76523958 | THERAPEUTIC USES OF ORAL HYPOGLYCEMIC DRUGS IN SOME PERIPHERAL ARTERIOPATHIES |
| Q78334733 | TOLAZAMIDE (TOLANASE) -- A NEW SULPHONYLUREA |
| Q78435238 | TREATMENT OF ADULT DIABETES |
| Q77067959 | TREATMENT OF DIABETES BY SYNTHETIC HYPOGLYCEMIC AGENTS. COURSE OF THE RELATIVE EFFICACY OF A NEW DRUG |
| Q76888682 | TREATMENT OF DIABETES IN ADULTS WITH DIMETHYLBIGUANIDE. (APROPOS OF 70 CASES) |
| Q78425133 | TREATMENT OF DIABETES IN CHILDREN |
| Q76635563 | TREATMENT OF DIABETES MELLITUS PATIENTS WITH CYCLAMID (K-386) |
| Q76879558 | TREATMENT OF DIABETES MELLITUS WITH SULFANILAMIDE PREPARATIONS |
| Q78385898 | TREATMENT OF STEROID DIABETES WITH ORADIAN |
| Q33621591 | Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management |
| Q57109419 | Targeting FXR and FGF19 to Treat Metabolic Diseases-Lessons Learned From Bariatric Surgery |
| Q34071861 | Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials |
| Q38028009 | Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings |
| Q78989818 | The "diabetoid states" of pregnancy and their treatment with oral antidiabetics |
| Q51746289 | The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. |
| Q39337962 | The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling |
| Q72963121 | The Clinical Value of the Glucogram and a New Approach to the Intravenous Glucose Tolerance Test |
| Q50099570 | The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review. |
| Q26748742 | The EMPA-REG outcome study: critical appraisal and potential clinical implications |
| Q26766298 | The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis |
| Q57163307 | The European Medicines Agency's approval of new medicines for type 2 diabetes |
| Q90945531 | The Exploration of Natural Compounds for Anti-Diabetes from Distinctive Species Garcinia linii with Comprehensive Review of the Garcinia Family |
| Q41623135 | The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus. |
| Q26746903 | The Possible Role of Flavonoids in the Prevention of Diabetic Complications |
| Q60916258 | The Potential of South African Herbal Tisanes, Rooibos and Honeybush in the Management of Type 2 Diabetes Mellitus |
| Q55114052 | The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus. |
| Q64057952 | The Role of Tocotrienol in Protecting Against Metabolic Diseases |
| Q72710191 | The Synthesis of Aryloxyureas |
| Q28078225 | The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review |
| Q26851917 | The antihyperglycemic effects of Rhizoma Coptidis and mechanism of actions: a review of systematic reviews and pharmacological research |
| Q36368998 | The cardiovascular effects of GLP-1 receptor agonists |
| Q38134902 | The cardiovascular safety of incretin-based therapies: a review of the evidence |
| Q78935387 | The combination DBI-sulfonylurea derivative for diabetes mellitus |
| Q91111293 | The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date |
| Q76469411 | The effect of Nl, n-butylbiguanide (W37) and Nl, beta-phenylethylbiguanide (W32) on alloxan and phlorrhizin diabetes and intestinal glucose absorption in rats |
| Q82127276 | The effect of age on the hypoglycemic depletion of glycogen in the central nervous system |
| Q41193270 | The effect of gemfibrozil on serum lipids in diabetic patients |
| Q39799380 | The effect of oral anti-diabetic agents (suphonyle ureas) on the excretion of intravenous biliary contrast media (author's transl) |
| Q35141884 | The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials |
| Q26999454 | The evolution of insulin glargine and its continuing contribution to diabetes care |
| Q72675955 | The hypoglycemic action of the Centaurea species. IV. Fractionation of active peptides with ammonium sulfate |
| Q33726074 | The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis |
| Q76493613 | The influence of adenosinetriphosphoric acid on the carbohydrate metabolism in hypoglycaemic animals |
| Q64056263 | The journey from gene knockout to clinical medicine: telotristat and sotagliflozin |
| Q51626749 | The lipid lowering effect of an anti-diabetic plant extract |
| Q22241441 | The management of gestational diabetes |
| Q50189173 | The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden |
| Q41353984 | The mechanisms of action of metformin |
| Q26991486 | The metabolic and mitogenic properties of basal insulin analogues |
| Q37597017 | The pharmacogenetics of type 2 diabetes: a systematic review |
| Q26999933 | The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies |
| Q36368988 | The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide |
| Q52316007 | The role of KATP channels in cerebral ischemic stroke and diabetes. |
| Q36877514 | The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes |
| Q37306857 | The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus |
| Q37248234 | The role of insulin detemir in overweight type 2 diabetes management. |
| Q35614956 | The role of metformin in the management of NAFLD |
| Q67378358 | The sugar decreasing effect of several insulin polymer derivatives following enteric administration to aniamls |
| Q26822399 | The therapy of insulin resistance in other diseases besides type 2 diabetes |
| Q64999167 | The use of GLP-1 receptor agonists in hospitalised patients: an untapped potential. |
| Q27011434 | The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: is continued use safe and effective? |
| Q74589789 | Theoretical & practical problems posed by the use of hypoglycemic sulfonamides. |
| Q54917687 | Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis. |
| Q92222818 | Therapeutic Benefit of Dillenia indica in Diabetes and Its Associated Complications |
| Q90470164 | Therapeutic effect of intensive glycemic control therapy in patients with traumatic brain injury: A systematic review and meta-analysis of randomized controlled trials |
| Q38611795 | Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review |
| Q94312306 | Therapeutic trials with synthetic hypoglycemic preparations in forms of mental dissociation |
| Q33879565 | Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps |
| Q34133889 | Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors |
| Q68235151 | Therapy in diabetology |
| Q91498437 | Thiazolidinediones: the Forgotten Diabetes Medications |
| Q38985705 | To what extent should dental implant placement be adopted as a standard for diabetic patients? |
| Q26829674 | Traditional Indian medicines used for the management of diabetes mellitus |
| Q34540987 | Treat-to-target trials: uses, interpretation and review of concepts |
| Q28077026 | Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists |
| Q41025468 | Treatment of Diabetes Mellitus Using iPS Cells and Spice Polyphenols |
| Q78986714 | Treatment of diabetes in the adult with phenformin (DBI). 202 cases treated in an ambulatory therapeutic trial in a 3-year period |
| Q76459825 | Treatment of diabetes with acetohexamide. Experience with 150 patients |
| Q76487446 | Treatment of diabetes with biguanidine derivatives |
| Q36108506 | Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance |
| Q36536290 | Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes |
| Q38710323 | Treatments for gestational diabetes: a systematic review and meta-analysis |
| Q78962934 | Two cases of malignant tumors with metastases apparently treated successfully with hypoglycemic coma |
| Q27694430 | Type 2 diabetes can be prevented with early pharmacological intervention |
| Q26776464 | Type 2 diabetes patients' and providers' differing perspectives on medication nonadherence: a qualitative meta-synthesis |
| Q33813768 | Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk |
| Q76943850 | USE OF A HYPOGLYCEMIC SULFONAMIDE: CHLORPROPAMIDE, IN THE ALCOHOLIC ABSTINENCE CURE. APROPOS OF 50 CASES |
| Q76927781 | USE OF ACETOHEXAMIDE (DYMELOR) IN DIABETIC PATIENTS WITH SECONDARY FAILURES TO ANTIDIABETIC DRUGS |
| Q78525677 | USELESS AND OTHERWISE INEFFECTIVE INSULIN THERAPY |
| Q38689189 | United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes |
| Q30392979 | Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum |
| Q92823941 | Use of Grape Pomace Phenolics to Counteract Endogenous and Exogenous Formation of Advanced Glycation End-Products |
| Q26779412 | Use of Insulin Lispro Protamine Suspension in Pregnancy |
| Q28072205 | Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations |
| Q92391699 | Use of fast-acting insulin aspart in insulin pump therapy in clinical practice |
| Q51246605 | Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification. |
| Q35038355 | Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. |
| Q22241290 | Use of metformin in the setting of mild-to-moderate renal insufficiency |
| Q37151347 | Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk |
| Q37199942 | Use of short-acting insulin aspart in managing older people with diabetes. |
| Q47276971 | Vanadium Compounds as PTP Inhibitors. |
| Q57801218 | Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus |
| Q37167474 | Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review |
| Q37428878 | Vildagliptin: a new oral treatment for type 2 diabetes mellitus |
| Q125770655 | Vitamin B12 levels in type 2 diabetic patients on Metformin compared to those never on Metformin: a cross sectional study in Tunisia. |
| Q33799982 | Vitamin B12 status in metformin treated patients: systematic review |
| Q76872164 | WHERE IS THE QUESTION OF DIABETES MELLITUS?PHYSIOLOGICAL AND PATHOGENIC ASPECTS, CLINICAL ASPECTS OF NON-SULFONAMIDE CHEMOTHERAPY (BIGUANIDES) |
| Q27026774 | Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake? |
| Q39227611 | What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis |
| Q28068342 | Why Antidiabetic Vanadium Complexes are Not in the Pipeline of "Big Pharma" Drug Research? A Critical Review |
| Q92687373 | David W. Boulton | field of work | P101 |
| Q1444550 | arteriosclerotic heart disease | drug or therapy used for treatment | P2176 |
| Q8255706 | Category:Anti-diabetic drugs | category's main topic | P301 |
| Q108324770 | tirzepatide | has use | P366 |
| Arabic (ar / Q13955) | خافضات سكر الدم | wikipedia |
| Процідыябетычныя сродкі | wikipedia | |
| Catalan (ca / Q7026) | Medicament antidiabètic | wikipedia |
| Antidiabetikum | wikipedia | |
| Antidiabetikum | wikipedia | |
| Diabetes medication | wikipedia | |
| Antidiabético | wikipedia | |
| Persian (fa / Q9168) | داروهای ضد دیابت | wikipedia |
| Antidiabétique | wikipedia | |
| טיפול תרופתי בסוכרת | wikipedia | |
| Antidijabetik | wikipedia | |
| Obat diabetes | wikipedia | |
| Anti-diabetici | wikipedia | |
| 経口血糖降下薬 | wikipedia | |
| 경구 혈당 강하제 | wikipedia | |
| min | Ubek antidiabetik | wikipedia |
| nb | Antidiabetika | wikipedia |
| Antidiabeticum | wikipedia | |
| Hipoglicemiante | wikipedia | |
| Antidiabetic | wikipedia | |
| Serbo-Croatian (sh / Q9301) | Antidijabetesni lek | wikipedia |
| Antidiabetikum | wikipedia | |
| Antidiabetik | wikipedia | |
| Antidijabetesni lek | wikipedia | |
| Antidiyabetik | wikipedia | |
| Thuốc trị đái tháo đường | wikipedia | |
| wuu | 抗糖尿病药 | wikipedia |
| 抗糖尿病药 | wikipedia |
Search more.